Ascendis Pharma A/SASNDNASDAQ
Loading
Year-over-year book value per share growth
Latest
7.10%
↑ 187% vs avg
Percentile
P79
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-8.13%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 7.10% |
| Q3 2025 | 8.01% |
| Q2 2025 | 1.89% |
| Q1 2025 | -78.86% |
| Q4 2024 | -6.40% |
| Q3 2024 | 70.33% |
| Q2 2024 | -33.74% |
| Q1 2024 | -62.70% |
| Q4 2023 | -97.21% |
| Q3 2023 | -213.14% |
| Q2 2023 | -61.31% |
| Q1 2023 | -36.62% |
| Q4 2022 | -41.85% |
| Q3 2022 | -25.75% |
| Q2 2022 | -8.18% |
| Q1 2022 | -27.71% |
| Q4 2021 | -9.76% |
| Q3 2021 | 42.43% |
| Q2 2021 | -14.51% |
| Q1 2021 | -4.70% |
| Q4 2020 | -13.19% |
| Q3 2020 | 82.38% |
| Q2 2020 | -13.46% |
| Q1 2020 | -8.39% |
| Q4 2019 | -10.10% |
| Q3 2019 | -2.92% |
| Q2 2019 | -13.43% |
| Q1 2019 | 148.21% |
| Q4 2018 | -8.33% |
| Q3 2018 | -8.95% |
| Q2 2018 | -11.15% |
| Q1 2018 | 77.25% |
| Q4 2017 | -18.31% |
| Q3 2017 | 59.33% |
| Q2 2017 | -18.50% |
| Q1 2017 | -12.34% |
| Q4 2016 | 84.43% |
| Q3 2016 | -18.58% |
| Q2 2016 | -10.95% |
| Q1 2016 | -15.34% |